Skip to main content

and
  1. No Access

    Article

    Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice

    Primary malignant central nervous system (CNS) tumors are the leading cause of childhood cancer-related death and morbidity. While advances in surgery, radiation, and chemotherapy have improved the survival ra...

    Joshua D. Bernstock, Nunzio Vicario, Rong Li, Li Nan in Cancer Gene Therapy (2020)

  2. No Access

    Article

    Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis

    IDH1 mutation has been identified as an early genetic event driving low grade gliomas (LGGs) and it has been proven to exerts a powerful epigenetic effect. Cells containing IDH1 mutation are refractory to epigene...

    Zhong Liu, Pulin Che, Juan J. Mercado, James R. Hackney in Journal of Neuro-Oncology (2019)

  3. Article

    Open Access

    Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression

    Pediatric high-grade brain tumors and adult glioblastoma are associated with significant morbidity and mortality. Oncolytic herpes simplex virus-1 (oHSV) is a promising approach to target brain tumors; oHSV G2...

    Gregory K. Friedman, Joshua D. Bernstock, Dongquan Chen, Li Nan in Scientific Reports (2018)

  4. No Access

    Article

    A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma

    Antiangiogenic therapy can rapidly reduce vascular permeability and cerebral edema but high doses of bevacizumab may induce selective pressure to promote resistance. This trial evaluated the efficacy of low do...

    Shiao-Pei Weathers, **aosi Han, Diane D. Liu in Journal of Neuro-Oncology (2016)

  5. No Access

    Article

    Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas

    Bevacizumab is widely used for treatment of high-grade gliomas and other malignancies. Because bevacizumab has been shown to be associated with neurocognitive decline, this study is designed to investigate whe...

    Asim K. Bag, Hyunki Kim, Yi Gao, Mark Bolding, Paula P. Warren in Journal of Neuro-Oncology (2015)

  6. Article

    Open Access

    S100A4 promotes pancreatic cancer progression through a dual signaling pathway mediated by Src and focal adhesion kinase

    S100A4 expression is associated with poor clinical outcomes of patients with pancreatic cancer. The effects of loss or gain of S100A4 were examined in pancreatic cancer cell lines. S100A4 downregulation remark...

    Pulin Che, Youfeng Yang, **aosi Han, Meng Hu, Jeffery C. Sellers in Scientific Reports (2015)

  7. No Access

    Article

    Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro

    Protein arginine methyltransferase 5 (PRMT5) catalyzes the formation of ω-NG,N′G-symmetric dimethylarginine residues on histones as well as other proteins. These modifications play an important role in cell d...

    **aosi Han, Rong Li, Wenbin Zhang, **uhua Yang in Journal of Neuro-Oncology (2014)

  8. No Access

    Article

    Management of Brain Metastases

    As systemic cancer therapies have improved, the natural history and importance of treating brain metastases continues to evolve. Historically, most patients with brain metastases have been managed with whole b...

    John G. Stewart MD, Stephen M. Sawrie MD, PhD in Current Treatment Options in Neurology (2010)

  9. No Access

    Article

    TGF-β1 up-regulates paxillin protein expression in malignant astrocytoma cells: requirement for a fibronectin substrate

    Cytokines can influence the interactions between members of the integrin cell adhesion receptor family and the extracellular matrix thereby potentially affecting cell function and promoting cell adhesion, grow...

    **aosi Han, Jerry E Stewart Jr, Susan L Bellis, Etty N Benveniste, Qiang Ding in Oncogene (2001)